Heart Lung Circ:维生素D有望跻身“万能神药”行列,新研究确定其又一大健康益处

2018-03-09 佚名 medicalxpress

一项新的研究表明,维生素D可以帮助保护心脏组织,防止心脏病发作后心力衰竭,这可能为现有的心力衰竭治疗方案提供低成本的补充。

一项新的研究表明,维生素D可以帮助保护心脏组织,防止心脏病发作后心力衰竭,这可能为现有的心力衰竭治疗方案提供低成本的补充。

韦斯特米德医学研究所的研究小组发现,维生素D可以防止心脏病发作后心脏组织过度结疤和增厚,这可能有助于降低心力衰竭的风险。研究人员使用老鼠模型来研究维生素D对心脏病发作后形成疤痕组织细胞的影响。这些细胞是心脏集落形成的单位成纤维细胞(cCFU-Fs).

维生素D有助于预防心力衰竭,但它与cCFU-Fs的相互作用还没有得到很好的证实。维生素D的好处越来越多,但我们仍然不完全理解它如何能机械地帮助心脏病的管理我们想知道更多关于维生素D如何保护心脏病发作后的心脏。

当心脏的血液供应受阻,导致组织损伤时,就会发生心脏病发作。这会引发炎症反应,ccfu-fs将受损组织替换为胶原基瘢痕组织。这是一个问题,因为疤痕的心脏组织可以降低心脏有效泵血的能力,这可能导致心力衰竭。

“我们的研究表明维生素D实际上阻止cCFU-Fs形成瘢痕组织。通过阻断cCFU-Fs,维生素D可能在降低心脏病发作后心力衰竭的风险方面发挥重要作用。”

心力衰竭是一种危及生命的疾病,全世界估计有二千三百万人受到影响。新的治疗方法对于减轻全球心力衰竭的负担是必要的。心血管疾病,包括心脏病发作和心力衰竭,是世界范围内主要的死亡原因,要改变这种状况,我们需要从每一个可能的角度研究心脏状况。这项研究首次证明了维生素D在调节心脏祖细胞中的作用,研究结果令人鼓舞。

“随着进一步的研究,维生素D可以证明是一个令人兴奋的,低成本的补充,我们希望这些发现用于临床试验。”

原始出处:

Thi Y.L. Le, Masahito Ogawa, Eddy Kizana, et.al. Vitamin D Improves Cardiac Function After Myocardial Infarction Through Modulation of Resident Cardiac Progenitor Cells. Heart, Lung and Circulation(2018)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=295111, encodeId=e91429511199, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 11 07:44:44 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356727, encodeId=dbb01356e274d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515874, encodeId=92f815158e456, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562868, encodeId=14531562868ad, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294579, encodeId=89d82945e90b, content=老药新用途.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 17:07:28 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294531, encodeId=b37629453155, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Fri Mar 09 12:53:04 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294529, encodeId=fa88294529d6, content=好的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Fri Mar 09 12:49:28 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-11 大爰

    学习了谢谢分享!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=295111, encodeId=e91429511199, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 11 07:44:44 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356727, encodeId=dbb01356e274d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515874, encodeId=92f815158e456, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562868, encodeId=14531562868ad, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294579, encodeId=89d82945e90b, content=老药新用途.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 17:07:28 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294531, encodeId=b37629453155, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Fri Mar 09 12:53:04 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294529, encodeId=fa88294529d6, content=好的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Fri Mar 09 12:49:28 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-11 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=295111, encodeId=e91429511199, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 11 07:44:44 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356727, encodeId=dbb01356e274d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515874, encodeId=92f815158e456, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562868, encodeId=14531562868ad, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294579, encodeId=89d82945e90b, content=老药新用途.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 17:07:28 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294531, encodeId=b37629453155, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Fri Mar 09 12:53:04 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294529, encodeId=fa88294529d6, content=好的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Fri Mar 09 12:49:28 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=295111, encodeId=e91429511199, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 11 07:44:44 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356727, encodeId=dbb01356e274d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515874, encodeId=92f815158e456, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562868, encodeId=14531562868ad, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294579, encodeId=89d82945e90b, content=老药新用途.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 17:07:28 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294531, encodeId=b37629453155, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Fri Mar 09 12:53:04 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294529, encodeId=fa88294529d6, content=好的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Fri Mar 09 12:49:28 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-11 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=295111, encodeId=e91429511199, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 11 07:44:44 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356727, encodeId=dbb01356e274d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515874, encodeId=92f815158e456, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562868, encodeId=14531562868ad, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294579, encodeId=89d82945e90b, content=老药新用途.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 17:07:28 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294531, encodeId=b37629453155, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Fri Mar 09 12:53:04 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294529, encodeId=fa88294529d6, content=好的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Fri Mar 09 12:49:28 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-09 1e0f8808m18(暂无匿称)

    老药新用途.学习了.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=295111, encodeId=e91429511199, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 11 07:44:44 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356727, encodeId=dbb01356e274d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515874, encodeId=92f815158e456, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562868, encodeId=14531562868ad, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294579, encodeId=89d82945e90b, content=老药新用途.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 17:07:28 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294531, encodeId=b37629453155, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Fri Mar 09 12:53:04 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294529, encodeId=fa88294529d6, content=好的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Fri Mar 09 12:49:28 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-09 sunfeifeiyang

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=295111, encodeId=e91429511199, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Mar 11 07:44:44 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356727, encodeId=dbb01356e274d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515874, encodeId=92f815158e456, content=<a href='/topic/show?id=0c7543588e8' target=_blank style='color:#2F92EE;'>#大健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43588, encryptionId=0c7543588e8, topicName=大健康)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d10894444, createdName=ms1467340776200723, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562868, encodeId=14531562868ad, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Mar 11 03:43:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294579, encodeId=89d82945e90b, content=老药新用途.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 17:07:28 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294531, encodeId=b37629453155, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Fri Mar 09 12:53:04 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294529, encodeId=fa88294529d6, content=好的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Fri Mar 09 12:49:28 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-09 Drhzm308

    好的.学习了

    0

相关资讯

JAMA:钙和维生素D降低老年人骨折风险的神话破灭了

2017年12月,发表在《JAMA》的一项由中国科学家进行的系统评价和Meta分析,考察了钙或维生素D补充与社区居住的老年人骨折发生率之间的相关性。

CLIN CANCER RES:维生素D转运基因多态性预测转移性结直肠癌患者结局

维生素D可以抑制Wnt信号及血管生成对结肠癌生长产生抑制性影响。那么,涉及到维生素D转运、代谢和信号的基因的SNPs与接受一线FOLFIRI和贝伐单抗治疗的转移性结直肠癌患者临床结局之间是否存在关系呢?CLIN CANCER RES近期发表了一篇文章研究这一问题。

SCI REP:维生素D与神经胶质瘤风险之间的关系!

由此可见,该研究结果并没有提供25(OH)D水平与所有形式的胶质瘤风险之间存在因果关系的证据。需要更多的证据来探讨25(OH)D水平与GBM风险之间的关系。

Nutrients:维生素D补充和非酒精性脂肪肝研究的现状和未来

非酒精性脂肪性肝病(NAFLD)的病理特征为肝细胞中异常累积的甘油三酯,在某些情况下伴有坏死性炎症活动和纤维化(脂肪性肝炎),并可能演变为肝硬化。

科普:维生素D有助降低患癌风险

人体维持较高的维生素D水平,可能有助降低罹患包括肝癌在内多种癌症的风险。

JCEM:维生素D状态和摄入量与认知功能有何关联

大家都知道血清25-羟基维生素D [25(OH)D]、饮食和补充维生素D可能影响认知结果。May A Beydoun等人在大量的种族和社会经济多样的美国城市成年人的各种认知领域的纵向变化检查维生素D状态和摄入量与性别/年龄特定和种族特定的关联,并将研究结果发表在近日的JCEM上。